Smart Immune Announces FDA Orphan Drug Status, IND Acceptance and Fast-Track Designation to Commence Phase 1/2 Clinical Trial of Proprietary Allogeneic T cell progenitor Product SMART 101 (ProTcell™) for AML and ALL
A l’hôpital Necker, une start-up mise sur un traitement post-greffe innovant
Smart Immune Announces the Launch of its T Cell Progenitor-based Platform of Next-Generation Biotherapies for Severe Infections and Leukemia .
Smart Immune will be in San Francisco
During the 38th annual J.P Morgan Healthcare conference. Following our latest announcement on the the launch of the T cell progenitor-based platform, we are looking forward to meeting there and share our latest progress.